These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11026483)

  • 1. Low affinity use-dependent NMDA receptor antagonists show promise for clinical development.
    Palmer GC; Widzowski D
    Amino Acids; 2000; 19(1):151-5. PubMed ID: 11026483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.
    Palmer GC
    Curr Drug Targets; 2001 Sep; 2(3):241-71. PubMed ID: 11554551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy.
    Löscher W
    Prog Neurobiol; 1998 Apr; 54(6):721-41. PubMed ID: 9560847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competitive Gly/NMDA receptor antagonists.
    Catarzi D; Colotta V; Varano F
    Curr Top Med Chem; 2006; 6(8):809-21. PubMed ID: 16719819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions.
    Jansen M; Dannhardt G
    Eur J Med Chem; 2003; 38(7-8):661-70. PubMed ID: 12932897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke.
    Palmer GC; Cregan EF; Bialobok P; Sydserff SG; Hudzik TJ; McCarthy DJ
    Ann N Y Acad Sci; 1999; 890():406-20. PubMed ID: 10668446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications.
    Trist DG
    Pharm Acta Helv; 2000 Mar; 74(2-3):221-9. PubMed ID: 10812962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
    Kornhuber J; Weller M
    Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy.
    Löscher W; Lehmann H; Behl B; Seemann D; Teschendorf HJ; Hofmann HP; Lubisch W; Höger T; Lemaire HG; Gross G
    Eur J Neurosci; 1999 Jan; 11(1):250-62. PubMed ID: 9987029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activators and inhibitors of the ion channel of the NMDA receptor.
    Klein RC; Castellino FJ
    Curr Drug Targets; 2001 Sep; 2(3):323-9. PubMed ID: 11554556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate-based therapeutic approaches: NR2B receptor antagonists.
    Gogas KR
    Curr Opin Pharmacol; 2006 Feb; 6(1):68-74. PubMed ID: 16376149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
    Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
    Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?
    Ikonomidou C; Turski L
    Lancet Neurol; 2002 Oct; 1(6):383-6. PubMed ID: 12849400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.
    Parsons CG; Danysz W; Quack G
    Neuropharmacology; 1999 Jun; 38(6):735-67. PubMed ID: 10465680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice.
    Geter-Douglass B; Witkin JM
    Psychopharmacology (Berl); 1999 Oct; 146(3):280-9. PubMed ID: 10541728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.